TOMUDEX (ZD1694), A NOVEL AND SPECIFIC THYMIDYLATE SYNTHASE INHIBITOR HAS PROMISING ACTIVITY IN ADVANCED COLORECTAL-CANCER

被引：0
|
作者：
VANCUTSEM, E
CUNNINGHAM, D
ZALCBERG, J
FRANCOIS, E
SCHORNAGEL, JH
ADENIS, A
GREEN, M
STARKHAMMER, H
AZAB, M
机构：
[1] TOMUDEX COLORECTAL CANC STUDY GRP,MACCLESFIELD,ENGLAND
[2] ZENECA PHARMACEUT,MACCLESFIELD,ENGLAND
来源：
GASTROENTEROLOGY | 1995年 / 108卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A548 / A548
页数：1
相关论文
共 40 条
  • [31] A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
    Berlin, J.
    Coveler, A. L.
    Ciombor, K. K.
    Kazmi, F.
    Graham, J.
    Peters, M. L.
    Clark, J. W.
    Myers, M.
    De Gramont, A.
    Evans, T. R. J.
    Blagden, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S568 - S568
  • [32] The deacetylase inhibitor NVP-LBH589 has potent anticancer activity in colon cancer, both as a single agent and in combination with inhibitors of thymidylate synthase
    Shao, W.
    Kwon, P.
    Growney, J.
    O'Connor, G.
    Wang, P.
    Feng, Y.
    Ladner, R.
    Fazzone, W.
    Fawell, S.
    Atadja, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII44 - VII44
  • [33] THYMIDYLATE SYNTHASE FROM UNTREATED HUMAN COLORECTAL-CANCER AND COLONIC MUCOSA - ENZYME-ACTIVITY AND INHIBITION BY 5-FLUORO-2'-DEOXYURIDINE-5'-MONOPHOSPHATE
    PETERS, GJ
    VANGROENINGEN, CJ
    LAURENSSE, EJ
    PINEDO, HM
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (03) : 263 - 267
  • [34] A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor- resistant advanced colorectal cancer
    Lal, R
    Dickson, J
    Cunningham, D
    Chan, I
    Norman, AR
    Ross, PJ
    Topham, C
    Middleton, G
    Hill, M
    Oates, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3023 - 3031
  • [35] Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy
    Chau, I
    Norman, AR
    Cunningham, D
    Waters, JS
    Topham, C
    Middleton, G
    Hill, M
    Ross, PJ
    Katopodis, R
    Stewart, G
    Oates, JR
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1453 - 1458
  • [36] Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy
    I Chau
    A R Norman
    D Cunningham
    J S Waters
    C Topham
    G Middleton
    M Hill
    P J Ross
    R Katopodis
    G Stewart
    J R Oates
    British Journal of Cancer, 2004, 91 : 1453 - 1458
  • [37] MECHANISMS OF RESISTANCE TO N-[5-[N-(3,4-DIHYDRO-2-METHYL-4-OXOQUINAZOLIN-6-YLMETHYL)-N-METHYLAMINO]-2-THENOYL]-L-GLUTAMIC ACID (ZD1694), A FOLATE-BASED THYMIDYLATE SYNTHASE INHIBITOR, IN THE HCT-8 HUMAN ILEOCECAL ADENOCARCINOMA CELL-LINE
    LU, K
    YIN, MB
    MCGUIRE, JJ
    BONMASSAR, E
    RUSTUM, YM
    BIOCHEMICAL PHARMACOLOGY, 1995, 50 (03) : 391 - 398
  • [38] CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
    Fakih, Marwan
    Desai, Jayesh
    Kuboki, Yasutoshi
    Strickler, John H.
    Price, Timothy Jay
    Durm, Greg Andrew
    Falchook, Gerald Steven
    Denlinger, Crystal S.
    Krauss, John C.
    Shapiro, Geoffrey
    Kim, Tae Won
    Park, Keunchil
    Coveler, Andrew L.
    Munster, Pamela N.
    Li, Bob T.
    Kim, June
    Henary, Haby Adel
    Ngarmchamnanrith, Gataree
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent anti-tumor activity in colorectal cancer models
    Baudat, Yves
    Neff-LaFord, Haley
    Nicolazzi, Celine
    Meyer, Dave
    Sigurjonsson, Johann Petur
    Lyski, Ryan
    Fantin, Valeria
    Brun, Marie-Priscille
    Chiron, Marielle
    Decary, Stephanie
    CANCER RESEARCH, 2023, 83 (07)
  • [40] Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells:: Induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms
    Coudray, AM
    Louvet, C
    Kornprobst, M
    Raymond, E
    André, T
    Tournigand, C
    Faivre, S
    De Gramont, A
    Larsen, AK
    Gespach, C
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (02) : 553 - 561
1234